The estimated Net Worth of Judy D. Olian is at least 5.44 百万$ dollars as of 13 July 2024. Ms. Olian owns over 1,800 units of United Therapeutics Corp stock worth over 2,563,537$ and over the last 10 years he sold UTHR stock worth over 2,455,388$. In addition, he makes 419,075$ as Independent Director at United Therapeutics Corp.
Judy has made over 27 trades of the United Therapeutics Corp stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 1,800 units of UTHR stock worth 623,142$ on 13 July 2024.
The largest trade he's ever made was exercising 12,601 units of United Therapeutics Corp stock on 31 July 2023 worth over 4,362,340$. On average, Judy trades about 2,330 units every 70 days since 2014. As of 13 July 2024 he still owns at least 7,405 units of United Therapeutics Corp stock.
You can see the complete history of Ms. Olian stock trades at the bottom of the page.
Dr. Judy D. Olian Ph.D. serves as Independent Director of the Company. She has served as President of Quinnipiac University since July 2018. Previously, she served as dean of the UCLA Anderson School of Management and the John E. Anderson Chair in Management from 2006 to 2018. Her research and business expertise centers on aligning organizational strategies and design with human resource systems and incentives, and managing top management teams. She began her UCLA appointment after serving as dean and professor of management at the Smeal College of Business Administration at Pennsylvania State University. Earlier, she served in various faculty and executive roles at the University of Maryland and its Robert H. Smith School of Business. Ms. Olian serves or has been a member of various advisory boards (including the U.S. Studies Centre at the University of Sydney, Peking University Business School's International Advisory Board and Catalyst, a leading global think tank for women in business) and served as Chairman of the Loeb Awards for Business Journalism. Born and raised in Australia, Ms. Olian received her B.S. in Psychology from the Hebrew University, Jerusalem and her M.S. and Ph.D. in Industrial Relations from the University of Wisconsin, Madison. She was the Chairman of AACSB International, the premier thought leadership and accreditation organization for leading global business schools, and also serves on the board of directors of Ares Management, L.P., a publicly-traded global alternative asset management firm, and Mattel, Inc., a publicly-traded multinational toy manufacturing company. She has served as a United Therapeutics director since 2015.
As the Independent Director of United Therapeutics Corp, the total compensation of Judy Olian at United Therapeutics Corp is 419,075$. There are 16 executives at United Therapeutics Corp getting paid more, with Martine Rothblatt having the highest compensation of 15,627,500$.
Judy Olian is 68, he's been the Independent Director of United Therapeutics Corp since 2015. There are 4 older and 16 younger executives at United Therapeutics Corp. The oldest executive at United Therapeutics Corp is Louis Sullivan, 86, who is the Independent Director.
Judy's mailing address filed with the SEC is 2000 AVENUE OF THE STARS, 12TH FLOOR, LOS ANGELES, CA, 90067.
Over the last 20 years, insiders at United Therapeutics Corp have traded over 68,910,395$ worth of United Therapeutics Corp stock and bought 229,703 units worth 13,655,671$ . The most active insiders traders include Martine A Rothblatt、David Zaccardelli、Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of 2,310,818$. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth 991,341$.
united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians
United Therapeutics Corp executives and other stock owners filed with the SEC include: